Market Analysis - Monthly Report - November, 2020 - Azithromycin
1.Overview of the Current Market Situation
In November, the price of Azithromycin was stable, and the slight change was exchange rate fluctuations. In November, the expansion plans of various factories have been completed, and the goods are not as tight as in previous months. Due to the pressure of domestic medical insurance, most of the production capacity of major manufacturers is used to make up for the gap in domestic demand. The goods of Ningxia Qiyuan and Zhejiang nexchem circulate more in foreign markets. Hebei Guolong exports a large amount of azithromycin amine to the Indian market, so there is no stock. In terms of the market, foreign epidemics continue, so the demand for azithromycin has been stable. The upstream raw material is Erythromycin thiocyanate, which is in short supply and prices are rising. This product has already restricted the export volume, and India may be short of azithromycin. All in all, the supply and demand of azithromycin were relatively balanced in November, so the price has been high and stable.

Manufacturer Price and Production Situation Statistics
Factory Name |
Quotation (USD/KG) |
Change (from last week) |
Plant capacity |
GUOBANG |
/ |
Stable |
500MT/YEAR |
CSPC |
124 |
Stable |
500MT/YEAR |
HEC |
122 |
Decline |
150MT/YEAR |
SHIXING |
122 |
Stable |
300MT/YEAR |
QIYUAN |
123 |
Stable |
200MT/YEAR |
GUOLONG |
122 |
Stable |
200MT/YEAR |
TAIYICIN |
121 |
Stable |
150MT/YEAR |
DONGFENG |
121 |
Stable |
150MT/YEAR |

Forecast of the Future Market Situation
Influential Factors |
Overview |
Price Trend |
Factory operating rate, inventory and cargo situation |
In December, the factory expanded its production capacity and stabilized production. The delivery time is no longer tight. There will be a small amount of inventory. |
Decline |
Market Demand |
In the international market, due to the expansion of the epidemic, demand continued to rise. But the demand in China has decreased. |
Stable |
Market Sentiment |
There are urgent customer needs, but the competition between suppliers will intensify. |
Decline |
Factory determination to raise prices |
Some factories still want to insist on high prices, and some factories have expanded their production capacity and want to quickly occupy more markets. The final pricing level still has to be considered by the market. |
Stable |
Upstream raw materials |
The price of Erythromycin Thiocyanate supply is tight, the price of Erythromycin thiocyanate will rise in December. |
increase |
Industry event |
/ |
/ |
In conclusion |
In December, The factory's production capacity expands and wants to quickly occupy the market, so the competition will become increasingly fierce. But the price of upstream raw materials rises, and the production cost of the factory will also increase. In addition, the overall market demand is also positive. Therefore, the rise and fall of the price of azithromycin in December is currently difficult to judge. |
Stable |
2026-09-08
Trade Alert
Delivering the latest product trends and industry news straight to your inbox.
(We'll never share your email address with a third-party.)
Related News
-
Egyptian Pharmaceutical Market Research
-
CPHI China 2023 | At the Heart of Pharma
-
A Guide Into What the Pharmaceutical Use of Hexamine Is
-
In line with the 8201, Hengrui Pharmaceutical plans the HER2 ADC in this way
-
$50 billion in products were 'returned' to rationalize those blockbuster BD deals
-
Tronsound long-acting IL-36R antibody obtained FDA clinical IND
-
Dapagliflozin is approved in the EU for the treatment of symptomatic chronic heart failure
-
The FDA accepted Zuranolone's NDA application and granted it priority review rights for the treatment of MDD and PDD
-
Asia Hong Pharma announced that it has co-developed an innovative tumor therapy based on AI+RNA technology route with ReviR
-
Ribo Biologics announced that the world's first FIH application for a siRNA drug targeting FXI has been successfully approved by HREC in Australia
Recommend Reading
-
Insufficient cost support + weak demand: Melamine continues its weak consolidation
-
Polyethylene prices reduced, short-term weak operation
-
Supply Contraction Bottoming Out—PP Expected to Remain Stable with Slight Increase in Early June
-
Both Supply and Demand Weak, PCs in Volatile Operation Mid-May
-
This Round of Refined Oil Retail Prices in China Will See a 'Triple Increase'
-
Premium Global Chemical Sourcing Requests (17 - 22 Jan, 2026)
-
FDA approves bemotrizinol, a long-used UV filter, for U.S. sunscreens
-
EDTA (Ethylenediaminetetraacetic acid): Chelation Therapy & Industrial Uses
-
Premium Global Chemical Sourcing Requests (8-10Jun, 2026)
-
Bivalirudin: Medical Uses, Properties, and Safety